Russell Schundler Sells 2,060 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the transaction, the general counsel now owns 486,027 shares of the company’s stock, valued at $7,086,273.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Price Performance

Shares of NASDAQ LQDA traded up $0.16 during midday trading on Wednesday, hitting $13.74. The company’s stock had a trading volume of 426,187 shares, compared to its average volume of 943,607. The business’s fifty day simple moving average is $14.77 and its two-hundred day simple moving average is $10.88. Liquidia Co. has a 1 year low of $5.71 and a 1 year high of $16.99. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -11.45 and a beta of 0.16.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The company had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Analysts anticipate that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Liquidia by 9.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock valued at $137,000 after acquiring an additional 989 shares in the last quarter. SkyView Investment Advisors LLC grew its holdings in Liquidia by 1.4% in the 4th quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company’s stock valued at $1,342,000 after buying an additional 1,571 shares during the last quarter. BNP Paribas Arbitrage SNC grew its holdings in Liquidia by 20.5% in the 1st quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock valued at $69,000 after buying an additional 1,702 shares during the last quarter. Chartwell Investment Partners LLC grew its holdings in shares of Liquidia by 6.0% during the 4th quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company’s stock worth $197,000 after purchasing an additional 1,769 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Liquidia by 7.1% during the 4th quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company’s stock worth $178,000 after purchasing an additional 1,845 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of recent research reports. Wedbush reiterated an “underperform” rating and issued a $3.00 target price on shares of Liquidia in a research report on Thursday, December 21st. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Liquidia in a research report on Wednesday, April 10th. HC Wainwright increased their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Bank of America increased their target price on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, LADENBURG THALM/SH SH raised their price objective on shares of Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).